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Aim. Recently, the utility of tumormarkers in the hepatocellular carcinoma (HCC) field has received a good deal of attention. Here,
we review and summarize the results of studies on the roles played by the 𝛼-fetoprotein (AFP) and prothrombin induced by the
absence of vitamin K or antagonist-II (PIVKA-II) responses in terms of the monitoring of outcomes and prediction of prognosis
after various HCC treatments.Methods. Studies lodged in PUBMED and that satisfied our inclusion criteria were reviewed. Results.
We reviewed 12 studies measuring both AFP and PIVKA-II responses in HCC patients treated in various ways. The results are
presented by treatment modality. Conclusion. Measurement of AFP and PIVKA II marker levels before and after HCC treatment is
clinically useful in monitoring of treatment outcomes and prognosis and in predicting recurrence and survival.
1. Introduction
Although treatments and surveillance have improved, hepa-
tocellular carcinoma (HCC) remains difficult to cure, partic-
ularly when the disease is progressive. Because only limited
treatment options are available, the prognosis is poor [1].
Thus, early diagnosis or detection of disease progression
after treatment remains key to effective control of HCC.
Imaging assessment remains the gold standard for evaluation
of responses after various HCC treatments [2–4]. However,
radiological analysis of HCC patients with vascular invasion
or multiple lesions may not yield clear data on disease
development, especially in cirrhotic patients. In addition,
extensive desmoplastic and inflammatory reactions, and
ischemic changes and tissue edema, develop after transar-
terial chemoembolization (TACE) or radiotherapy and may
mask improvement in tumor size that is normally detectable
by conventional imaging modalities, including radiology [5].
One possible way to deal with this limitation is via mea-
surement of tumormarkers, yielding information ancillary to
imaging data. Such markers have been studied previously [6,
7]. Measurement of 𝛼-fetoprotein (AFP) level is simple and is
already used widely for routine surveillance and noninvasive
diagnosis of HCC and to evaluate prognosis and monitor
recurrence following treatment [5, 6]. However, AFP serum
levels can also be increased in patients with other nontumor-
ous hepatic disorders, including acute and chronic hepatitis
of any type, cirrhosis, and/or massive hepatic necrosis, and
may reflect (general) hepatic inflammatory and regenerative
activity [6, 8, 9]. However, serum prothrombin induced
by the absence of vitamin K or antagonist-II (PIVKA-II)
measurement not only more specifically differentiates HCC
from other hepatic diseases [10, 11], but PIVKA-II levels are
not also usually correlated with those of AFP [12, 13]. Thus,
measures of PIVKA-II and AFP are independent. Although
the AFP serum level reflects the intrahepatic tumor burden,
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assessment of serum PIVKA-II level reflects the extent of
vascular invasion, including portal vein thrombosis and
extrahepatic disease extension [14], and is regarded as com-
plementary to serumAFPmeasurement.Thus, measurement
of both PIVKA-II and AFP levels may yield useful informa-
tion on treatment response and prognosis in HCC patients.
Because the half-lives of the two serummarkers are only a few
weeks [15], changes in serumAFP and PIVKA-II levels before
and after treatmentmay provide clinically useful information
on both treatment outcome and prognosis.The clinical utility
of simultaneous AFP and PIVKA-II measurement was first
report by Aoyagi et al. in 1996 [16]. Since then, many studies
have focused onuse of a combination of the levels of these two
markers to assess treatment response, to predict prognosis
and indeed to diagnose HCC [17–23].
Multimodal treatment is mandatory in HCC patients,
and the prognostic cutoff values, and predictive powers, of
AFP and PIVKA-II levels will differ according to the chosen
treatment modality.Therefore, we reviewed and summarized
the results of studies on the utilities of AFP and PIVKA-II
levels in monitoring of treatment outcomes and predicting
prognosis.
2. Methods
2.1. Search Strategy. Acomputerized English-language search
of PUBMED was performed in September 2013. Studies
published at any time were included. After a preliminary
search of the MeSH database, we used the terms “AFP and
PIVKA-II,” “AFP and DCP,” “combination tumor markers,”
“HCC,” “treatment response,” and “prognosis” to search titles
and/or abstracts.
2.2. Study Eligibility and Critical Appraisal. We carefully
reviewed all studies on AFP and PIVKA-II markers in the
HCC context and selected studies (1) dealing with both AFP
and PIVKA-II, (2) featuring measurement of both tumor
markers before and after treatment of HCC, and, (3) focusing
on the roles played by both tumor markers in assessing
treatment outcomes or predicting prognosis and survival.We
found 12 studies thatmet these criteria when investigating the
utilities of various HCC treatment modalities (Table 1).
3. Results
3.1. Serum AFP and PIVKA-II Levels in Patients Who Under-
went Curative Hepatic Resection to Treat HCC. Six studies
measured both AFP and PIVKA-II levels in patients who
underwent curative hepatic resection [20, 24–28].
3.1.1. Monitoring Treatment Outcomes. Yamamoto et al.
reported that the favorable predictive values of pretreatment
AFP and PIVKA-II levels in terms of postoperative recur-
rence had AUROCs of 0.79 and 0.91, respectively [26]. The
sensitivity and specificity of recurrence detection improved
simultaneously when both AFP and PIVKA-II levels were
measured (sensitivity, 66.7%; specificity 47.9%) compared to
those obtained when AFP levels alone (sensitivity, 60.1%;
specificity, 45.2%) or PIVKA-II levels alone (sensitivity,
62.9%; specificity, 47.9%) [20] were assessed. Patients with
high pretreatment levels of AFP and PIVKA-II experienced a
significantly higher incidence of tumor recurrence after cura-
tive treatment [20, 25], associated with the more unfavorable
tumor characteristics of patients with higher levels of AFP
and PIVKA-II [20, 21]. Chon et al. found that pretreatment
AFP and PIVKA-II levels were significantly higher in patients
with microscopic vessel invasion, or multiple tumors, com-
pared to others [20]. The roles played by tumor markers in
reflecting microscopic vessel invasion or tumor multiplicity
can compensate for limitations of current prognostic systems.
The concern was whether changes in tumor marker
levels after treatment would yield additional information
on patients who underwent curative resection [20, 24, 25,
28]. Changes in tumor marker levels after curative hepatic
resection provide information on both the pattern and
probability of recurrence. In one study, high preoperative
serum AFP and PIVKA-II levels were associated with early
recurrence (within 6 months) after curative resection [26].
Such patients had higher preoperative AFP and PIVKA-II
values than did those who developed recurrences >6 months
after surgery. Also, patients experiencing extrahepatic recur-
rences had higher preoperative marker levels than did those
with intrahepatic recurrences.
3.1.2. Prediction of Survival. SerumAFP and PIVKA-II levels
were also predictive of survival in many studies [20, 24–27].
Changes in tumor marker levels 3 months after operation
significantly predicted HCC recurrence [20]. If marker levels
did not fall, recurrence was likely [20, 24, 25]. Patients
with high AFP and PIVKA-II levels after curative treatment
experienced significantly poorer overall survival than those
with normal marker levels [25]. In addition, not only high
levels of markers per se, but also shorter doubling times of
increases in marker levels were linked to significantly poorer
disease-free and overall survival [27].Thus, rapid elevation of
marker levels reflects aggressive behavior of remnant tumors
after curative treatment.
Upon multivariate analysis to evaluate the predictive
values of marker levels in terms of survival, elevated serum
levels of AFP and/or PIVKA-II both before and after surgery
independently predicted disease-free or overall survival, as
did tumor size, tumor number, and the existence of vascular
invasion [20, 24, 25].The numbers of markers elevated before
operation and shorter doubling times of marker values were
also predictive of survival [25, 27].
3.2. Serum AFP and PIVKA-II Levels in Patients with TACE.
Two studies have examined the kinetics of both AFP and
PIVKA-II levels in HCC patients treated via transarterial
chemoembolization (TACE) [22, 29].
3.2.1. Monitoring Treatment Outcomes. Radiological mor-
phology after TACE is sometimes nonhomogenous and
inconsistent because of irregular uptake of lipiodol and
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Table 1: Studies regarding both AFP and PIVKA-II in the patients who underwent various treatment modalities for HCC.
Author Year Number ofpatients
Treatment
modality
Tumor
marker
Cutoff value of
markers
Definition of tumor
marker response
(change from baseline)
Toyoda et al. [24] 2012 173 Curativeresection
AFP
AFP-L3
PIVKA-II
20 ng/dL
5%
40mAU/mL
—
Chon et al. [20] 2012 267 Curativeresection
AFP
PIVKA-II
20 ng/dL
40mAU/mL —
Nanashima et al. [25] 2011 470 Curativeresection
AFP
PIVKA-II
20 ng/mL,
200 ng/mL†
40mAU/mL,
400mAU/mL†
—
Yamamoto et al. [26] 2009 714 Curativeresection
AFP
PIVKA-II
20 ng/mL
40mAU/mL —
Masuda et al. [27] 2010 210 Curativeresection
AFP
PIVKA-II
20 ng/mL
40mAU/mL —
Nanashima et al. [28] 2006 63 Curativeresection
AFP
PIVKA-II
20 ng/mL
40mAU/mL —
Lee et al. [22] 2013 115 TACE AFPPIVKA-II
20 ng/mL
40mAU/mL ≥50% reduction
Park et al. [29] 2012 327 TACE AFPPIVKA-II
10 ng/mL
40mAU/mL ≥50% reduction
Lee et al. [23] 2012 6067
HAIC
CCRT
AFP
PIVKA-II
20 ng/mL
20mAU/mL ≥20% reduction
Park et al. [14] 2013 111 CCRT AFPPIVKA-II
200 ng/mL
60mAU/mL ≥50% reduction
Kuzuya et al. [30] 2011 48 Sorafenib AFPPIVKA-II —
‡ —
Nakazawa et al. [31] 2013 59 Sorafenib AFPPIVKA-II
10 ng/mL
40mAU/mL
≥20% increase Twofold
increase
†Patients were divided into 3 groups with low and high cutoff values of tumor markers in this study.
‡Tumor marker ratio was evaluated in this study.
necrosis, evident on follow-up imaging, and this can com-
promise imaging-based measurements of tumor responses
[32, 33]. Lee et al. and Park et al. evaluated the serum
levels of AFP and PIVKA-II in efforts to overcome this
limitation [22, 29]. Radiological responses were assessed
using the modified Response Evaluation Criteria in Solid
Tumors (mRECIST), and each patient was considered to
show a complete response (CR), a partial response (PR),
stable disease (SD), or progressive disease (PD), as described
in previous reports [3]. When the percentage declines in
tumormaker levels after treatment (frompretreatment levels)
were evaluated, the reductions in both AFP and PIVKA-II
levels in patients exhibiting a CR or PR were significantly
greater than in those with SD or PD [29]. In addition, a strong
association between the radiological response and serum
AFP and PIVKA-II levels was evident [29]. However, such an
association was questioned in another study [22]. The AFP
serum level was significantly correlated with the radiological
response, but the serum level of PIVKA-II was not.
3.2.2. Prediction of Survival. Park et al. found significant
differences in median overall survival times between tumor
marker responders and nonresponders [29]. Upon mul-
tivariate analysis, the PIVKA-II and AFP responses were
significant indicators of overall survival independent of host,
tumor, and serological factors, when pretreatment values
were compared with those 3 and 6 months after treatment.
Lee et al. found that pretreatment AFP levels indepen-
dently predicted progression-free survival, but pretreatment
PIVKA-II levels did not. In terms of overall prediction of
survival, the pretreatment PIVKA-II level, the presence of
cirrhosis, the tumor number, and the AFP response were all
independent predictors [22]. The cited authors performed a
subanalysis to determine whether a combination of the AFP
and PIVKA-II responses would improve the prognostic value
of either alone. After stratifying patients with AFP and/or
PIVKA-II responses into combined tumor marker respon-
ders, and those without AFP and PIVKA-II responses into
combined tumormarker nonresponders, overall survival was
significantly longer in the former than the latter group (39.0
versus 21.5 months; log-rank test, 𝑃 = 0.011). In addition,
the combined tumor marker response was an independent
predictor of overall survival, together with tumor size and
the presence of cirrhosis. However, in terms of prediction of
progression-free survival, no difference was evident between
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the two groups. Thus, the combined tumor marker response
did not independently predict progression-free survival upon
multivariate analysis.
3.3. Serum AFP and PIVKA-II Levels Patients Receiving
HAIC or CCRT to Treat HCC. Two studies examined the
kinetics of both AFP and PIVKA-II levels in HCC patients
undergoing hepatic artery infusional chemotherapy (HAIC)
or concurrent chemoradiation therapy (CCRT) [14, 23].
3.3.1. Monitoring Treatment Outcomes. Lee et al. evaluated
the clinical utilities of AFP and PIVKA-II levels as predictors
of treatment outcomes in patients with advanced HCC
receiving HAIC (𝑛 = 60) or CCRT (𝑛 = 67) [23]. In
patients who underwent HAIC, the overall response (both
CR and PR, according to WHO criteria) was significantly
higher in AFP responders than nonresponders (36.0% versus
8.6%, 𝑃 = 0.009) and also in PIVKA-II responders than
nonresponders (50.0% versus 2.5%, 𝑃 < 0.001). However, no
difference in disease control rate (the total of CR, PR, and
SD, according to WHO criteria) between AFP or PIVKA-
II responders and nonresponders was evident. In patients
who underwent CCRT, only the overall response rate of
PIVKA-II responders was significantly better than that of
PIVKA-II nonresponders (42.2% versus 13.6%, 𝑃 = 0.019);
neither the overall response nor the disease control rate of
AFP responders differed from those of AFP nonresponders.
Another study on the clinical utilities of AFP and PIVKA-
II levels in patients undergoing CCRT (𝑛 = 111) focused
on whether a combination of AFP and PIVKA-II marker
levels could be used to subdivide patients into prognostic
groups [14]. Four groups were defined: A↓P↓ [AFP response
(+) and PIVKA-II response (+)]; A↓P↑ [AFP response (+)
and PIVKA-II response (−)]; A↑P↓ [AFP response (−) and
PIVKA-II (+)]; A↑P↑ [AFP response (−) and PIVKA-II (−)].
Not only the overall response but also the disease control rate
was the best in the A↓P↓ group, followed (in order) by the
A↓P↑, A↑P↓, and A↑P↑ groups. Notably, this study showed
that treatment outcome and prognosis differed significantly
among patients varying in the PIVKA-II response, evenwhen
patients exhibited an AFP response. In addition, a combina-
tion of the responses of both tumor markers predicted the
pattern of disease progression, extrahepatic versus intrahep-
atic. Extrahepatic disease occurred more frequently in the
A↓P↑ group and intrahepatic disease more frequently in the
A↑P↓ group (50.0% versus 28.6% for extrahepatic disease;
50.0 versus 71.4% for intrahepatic disease, respectively; 𝑃 =
0.001).This is because the serumAFP level reflects the tumor
burden, whereas the serum PIVKA-II level reflects the extent
of vascular invasion (portal vein thrombosis and extrahepatic
disease extension) [34].
3.3.2. Prediction of Survival. In patients who underwent
HAIC, AFP responders experienced significantly better over-
all survival than did AFP nonresponders (17.3 versus 6.4
months, 𝑃 < 0.001), whereas the survival of PIVKA-II
responders did not differ from that of PIVKA-II nonre-
sponders [23]. Similar results were seen in patients who
underwent CCRT. The overall survival of AFP responders
was significantly longer than that of AFP nonresponders (17.6
versus 8.7 months, 𝑃 = 0.014), but PIVKA-II responders
and nonresponders did not significantly differ in this context.
Rather, PIVKA-II responders among CCRT-treated patients
showed significantly better progression-free survival than did
nonresponders (9.2 versus 3.1 months, 𝑃 < 0.001). Multi-
variate analysis revealed that the AFP response was indepen-
dently predictive of overall survival in patients treated with
HAIC or CCRT, whereas the PIVKA-II response predicted
only progression-free survival in patients treated with CCRT.
Park et al. found that the prognoses of AFP responders could
be further divided in terms of whether such patients were
also PIVKA-II responders [14]. Patients in the A↓P↓ group
had significantly longer progression-free and overall survival
than did those of the A↓P↑ group (16.2 versus 5.1 months,
𝑃 = 0.009; 26.3 versus 7.3 months, 𝑃 = 0.017, resp.) [14]. In
addition, of patients who showed a discordant tumor marker
response (A↓P↑ or A↑P↓), those of the A↑P↓ groupwhowere
AFP nonresponders had better progression-free and overall
survival than did A↓P↑ patients (10.1 versus 5.1 months, 𝑃 =
0.038; 22.4 versus 7.3months,𝑃 = 0.038, resp.).Thepredictive
power (in terms of survival) of the two combined tumor
markers was better than that of AFP alone, and comparable to
that of the radiological response, according to the mRECIST
criteria.
3.4. Serum AFP and PIVKA-II Levels in Patients Given
Sorafenib to Treat HCC. Two studies investigated the kinetics
of both AFP and PIVKA-II after administration of sorafenib
to patients with advanced HCC [30, 31].
3.4.1. Monitoring Treatment Outcomes. Kuzuya et al. [30]
measured tumor marker ratios (the concentrations of tumor
markers 2 and 4 weeks after treatment, divided by the values
before treatment). At 2 weeks, the AFP (but not the PIVKA-
II) ratio was significantly higher in patients with PD than in
thosewith PR or SD.At 4weeks, both ratios were significantly
higher in patients with PD than in those with PR or SD.
The median AFP level did not change by either 2 or 4
weeks after commencement of sorafenib in the PR + SD
group, but a significant increase was evident in the PD group.
Similarly, Nakazawa et al. found an early increase in AFP
level (more than 20% that of the baseline value) within
4 weeks after commencement of sorafenib in PD patients
[31]. However, median PIVKA-II levels did not fall after
commencement of sorafenib, even in the PR + SD group, in
two studies [30, 31]. Rather, the median PIVKA-II levels at
both 2weeks and 4weeks increased significantly over baseline
in both the PR + SD and PD groups [30]. Such elevation of
PIVKA-II levels even in patients who are responding well
had been reported in previous studies [35, 36]. One possible
explanation is that sorafenib-mediated inhibition of angio-
genesis rendered tumor cells hypoxic, increasing PIVKA-
II production [30, 36]. Therefore, the elevated PIVKA-II
levels seen after administration of sorafenib may indicate not
only tumor progression but also tumor responsiveness, and
caution must be exercised when interpreting changes in AFP
and PIVKA-II levels together.
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3.4.2. Prediction of Survival. Kuzuya et al. assessed the cumu-
lative time to progression (using the RECIST criteria) and
cumulative overall survival after dividing patients into two
groups: those with low and high tumormarker ratios 4 weeks
after treatment [30]. First, the median time to progression
was significantly longer in the low than the high AFP ratio
group (3.5 versus 2.1 months, 𝑃 = 0.021), and the median
overall survival tended to be higher in the former than the
latter group, but the difference was not statistically significant
(9.3 versus 5.1 months, 𝑃 = 0.089). In terms of PIVKA-
II levels, no significant difference in either cumulative time
to progression or overall survival was evident between the
low and high PIVKA-II ratio groups. Nakazawa et al. found
that pretreatment PIVKA-II levels over 1,000mAU/mL and
an early increase in AFP level were independent predictors
of poor overall survival. Further, an early rise in AFP level
was the only independent predictor of poor progression-free
survival [31].
4. Summary and Perspectives
The clinical utilities of tumor markers of HCC remain
controversial. The potential roles played by tumor markers
tend to be underrated in western reports, being considered
of greater value in eastern settings. Recently, a combination
of AFP and PIVKA-II levels has been recommended for
diagnosis of HCC malignancy in Japan [17]. Most prior
work on tumor markers focused on their possible diagnostic
utility. However, as we have shown, measurement of marker
levels both before and after HCC treatment is clinically valu-
able to monitor treatment outcomes (in combination with
radiological analysis) and to predict prognosis, recurrence,
and survival. Serum biomarkers demonstrate great potential
for use in monitoring therapeutic effects and for predicting
outcomes early in HCC treatment. Earlier studies used
different “normal” values of AFP and PIVKA-II levels and
variously defined measures of tumor response. It is necessary
to standardize these measures during future evaluation of the
importance of tumor markers in patients treated for HCC.
In addition, HCC patient subdivision into groups defined by
simultaneous consideration of AFP and PIVKA-II levels may
yield interesting results.
In conclusion, measurement of a combination of tumor
markers before and after HCC treatment is clinically valuable
in terms of monitoring treatment outcomes (together with
radiological analysis), and to predict prognosis recurrence,
and survival.
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